Purespring Therapeutics key facts
- Developer of kidney-targeted gene therapy products intended for the treatment of chronic glomerular kidney diseases, including rare inherited and non-genetic conditions.
- Purespring Therapeutics’s last known valuation is $81.6M.
- It has raised $164.7M; the latest was Early Stage VC ($105.8M) in Oct 2024.
- Notable investors include British Business Bank, Sofinnova Partners, Forbion, Gilde Healthcare, University of Bristol — 6 tracked in total.
- Status: Privately Held (backing).
Who backs Purespring Therapeutics
6- ·Watch Purespring Therapeutics: the Monday email on marks, rounds and moves
Purespring Therapeutics funding rounds
No funding rounds for Purespring Therapeutics are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
Purespring Therapeutics valuation
Purespring Therapeutics's last known valuation is $81.6 million. The figure stands until a priced round, a secondary trade or an institutional fund mark prices the stock again.
Purespring Therapeutics investors
6 investors are on record for Purespring Therapeutics, including British Business Bank, Sofinnova Partners, Forbion and Gilde Healthcare.
About Purespring Therapeutics
Developer of kidney-targeted gene therapy products intended for the treatment of chronic glomerular kidney diseases, including rare inherited and non-genetic conditions. The company offers a podocyte-focused gene therapy platform that directs vectors to glomerular structures, aims to maintain kidney filtration function, concentrates on modulating complement signalling in the glomeruli through its lead program for IgA nephropathy, and advances additional candidates for monogenic podocyte disorders such as NPHS2 nephropathy and glomerular basement membrane deficiencies, enabling nephrologists healthcare providers researchers and patients to access disease-modifying therapeutic approaches aimed at delaying or preventing progression to end-stage renal disease dialysis or kidney transplant.
- Sector
- Healthcare
- HQ
- London, United Kingdom
- Founded
- 2020
- Employees
- 50
- Website
- purespringtx.com/
- Ownership
- Privately Held (backing)
Is this your company? Sign in with your work email to keep it current, or tell us what's wrong.
Purespring Therapeutics’s last known valuation. A PrivateMarketView mark is published once fund marks, secondary prints or a priced round let us confirm it.